Form 4: Teva Pharma Exec Hughes Acquires 141,478 RSUs

Teva Pharmaceutical Industries Ltd. Executive Vice President Eric A. Hughes acquired 141,478 restricted share units, which are subject to time-based vesting until March 3, 2026.

Summary

• Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer of Teva Pharmaceutical Industries Ltd., acquired 141,478 Restricted Share Units (RSUs).
• The transaction date for the acquisition of these RSUs was January 27, 2026.
• These RSUs were received upon the satisfaction of performance criteria for previously granted performance share units.
• The acquired units are now subject to time-based vesting and are scheduled to fully vest on March 3, 2026.
• Each RSU represents a contingent right to receive one ordinary share or its cash equivalent at settlement, at the discretion of the Human Resources and Compensation Committee.
• Following this transaction, Eric A. Hughes beneficially owns 141,478 Restricted Share Units.
• Ordinary Shares may be represented by American Depositary Shares, with each ADS currently representing one Ordinary Share.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the alignment of executive incentives with shareholder interests through equity ownership, which is a standard and healthy corporate governance practice.

Positives

• The acquisition of Restricted Share Units by a key executive like Eric A. Hughes aligns management's interests with those of shareholders, as the value of these units is tied to the company's stock performance.
• The grant of RSUs upon satisfaction of performance criteria indicates that the executive met specific targets, which can be viewed positively regarding operational execution.

Future Outlook

The acquired Restricted Share Units are subject to time-based vesting and will fully vest on March 3, 2026, indicating a future milestone for the executive's compensation.

Industry Context

StockSavvy.ai notes that executive compensation through equity grants like Restricted Share Units is a standard practice across the pharmaceutical and biotechnology industries. This mechanism is widely used to align the long-term interests of key management personnel with those of the company's shareholders, encouraging sustained performance and value creation.

Comparison to Industry Standards

• Executive compensation through equity grants, such as Restricted Share Units, is a common and accepted practice within the global pharmaceutical industry, including major players like Pfizer, Merck, and Johnson & Johnson.
• The structure, where units are granted upon meeting performance criteria and then subject to time-based vesting, is a standard approach to incentivize both short-term performance and long-term retention.
• While the specific number of units granted varies based on company size, executive role, and overall compensation philosophy, the mechanism itself is consistent with industry benchmarks.

Stakeholder Impact

• Shareholders: The grant of RSUs to a key executive can positively impact shareholders by aligning management's financial incentives with the company's long-term stock performance and value creation.
• Employees: This transaction is specific to a senior executive's compensation and does not directly impact the broader employee base, though it reflects the company's executive compensation strategy.

Next Steps

• The 141,478 Restricted Share Units are scheduled to vest on March 3, 2026, at which point they will convert into ordinary shares or their cash equivalent.

Key Dates

Keywords

TEVA, Restricted Share Units, RSU, Executive Compensation, Insider Transaction, Form 4, Equity Grant, Teva Pharmaceutical Industries